Charcot neuro-osteoarthropathy—often simply called the Charcot foot—is one of the most misunderstood and under-recognized complications of diabetes. It is a progressive condition in which the bones and joints of an insensate foot fracture, dislocate, and collapse, frequently without the pain that would normally prompt a person to seek care. Because the earliest signs mimic more common problems such as cellulitis, gout, or a sprain, the diagnosis is often missed for weeks or months. That delay matters: untreated Charcot deformity can lead to ulceration, infection, and ultimately amputation. This article reviews what current peer-reviewed literature tells us about how the condition develops, how it is diagnosed, and how it is managed.
What Charcot Neuroarthropathy Is and Why It Develops
Charcot neuroarthropathy occurs almost exclusively in people who have lost protective sensation from diabetic peripheral neuropathy. Its pathophysiology is now understood to be multifactorial. In a review tracing the disease “from the laboratory to the bedside,” Pitocco and colleagues describe how uncontrolled local inflammation drives excessive bone resorption through the RANKL/RANK/OPG signaling pathway, weakening bone at the same time that neuropathy removes the pain signals that would otherwise protect the foot from repetitive trauma (Pitocco et al., 2019). Contributing factors include autonomic dysfunction, advanced glycation end-products, and the mechanical stress of continued walking on a compromised foot.
The condition is not rare, and it appears to be an increasing burden. A retrospective analysis of Texas hospital discharge data found that both overall and age-standardized rates of Charcot neuroarthropathy rose across most of the study period from 2006 to 2016, and that major and minor amputations among affected patients increased as well (Cole & Jupiter, 2024). The authors emphasized the need for standardized strategies for earlier diagnosis and management.
Recognizing and Diagnosing the Acute Charcot Foot
The single most important message in the literature is that diagnosis depends on clinical suspicion. In the acute phase, the foot or ankle is typically red, warm, and swollen, often with a temperature difference of several degrees compared with the opposite limb, and frequently with little or no pain in a person with neuropathy (Schweitzer & Rockhill, 2022). Because these features overlap with infection and other inflammatory conditions, clinicians are advised to consider Charcot in any neuropathic patient who presents with a unilateral hot, swollen foot until proven otherwise.
The Role of Imaging
Plain radiographs may appear normal early in the disease, before bony changes have developed. Advanced imaging—particularly MRI—is valuable for detecting the early bone marrow edema of acute Charcot and for helping distinguish it from osteomyelitis, a differential diagnosis that remains one of the most difficult challenges in this field (Pitocco et al., 2019). The 2023 guidelines from the International Working Group on the Diabetic Foot (IWGDF), the first international evidence-based guidelines dedicated to active Charcot neuro-osteoarthropathy, provide a structured approach to combining clinical assessment with imaging to reach and confirm the diagnosis (Wukich et al., 2023).
Management: Offloading Is the Foundation
Once acute Charcot is suspected, treatment should begin immediately—before radiographic confirmation if necessary—because the goal is to halt bone destruction while inflammation is active. Across reviews, offloading and immobilization are described as the cornerstone of care. The affected limb is placed in a total contact cast or equivalent device, and the patient remains non-weight-bearing until the fractured and dislocated bones have consolidated (Schweitzer & Rockhill, 2022). This process is measured in months, not weeks, and treatment is typically guided by resolution of the temperature difference between the two feet and by radiographic evidence of healing.
Patient education and expectation-setting are repeatedly identified as decisive factors. Because the foot does not hurt, adherence to prolonged immobilization is difficult, yet premature return to weight-bearing is a major cause of progressive deformity (Schweitzer & Rockhill, 2022). Pharmacological therapies such as bisphosphonates and calcitonin have been studied as adjuncts aimed at the underlying bone turnover, but the evidence supporting them remains limited, and offloading continues to be the mainstay.
When Surgery Is Considered
Surgery is generally reserved for feet that develop unstable or severe deformity, recurrent ulceration over bony prominences, or a shape that cannot be accommodated in footwear or bracing. Reconstructive procedures aim to restore a stable, plantigrade foot that can be protected long-term, and are best delivered within a multidisciplinary limb-salvage framework (Wukich et al., 2023; Schmidt & Holmes, 2018).
Prevention, Surveillance, and Prognosis
Long-term outcomes depend heavily on ongoing, specialized care. Schmidt and Holmes note that patients with Charcot neuroarthropathy—especially those with a coexisting diabetic foot ulcer or midfoot and rearfoot involvement—require consistent multidisciplinary follow-up, and that predictors of poor outcome include a related ulcer and progressive bony change on serial radiographs (Schmidt & Holmes, 2018). Preventive measures center on the fundamentals of diabetic foot care: glycemic control, regular foot examinations to detect early temperature and appearance changes, protective footwear, and patient education so that warning signs prompt rapid evaluation (Bansod et al., 2023).
Key Takeaways
Charcot neuroarthropathy is an inflammatory, neuropathy-driven condition that can silently destroy the architecture of the foot. Early recognition of a hot, swollen, often painless foot in a person with diabetic neuropathy is critical, and imaging—especially MRI—helps confirm the diagnosis and separate it from infection. Prompt, prolonged offloading and immobilization remain the foundation of treatment, with surgery reserved for unstable or severe deformity. With early diagnosis, sustained offloading, multidisciplinary care, and preventive foot surveillance, the risk of deformity, ulceration, and amputation can be substantially reduced.
References
Wukich, D. K., Schaper, N. C., Gooday, C., et al. (2023). Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews, 40(3), e3646.
Cole, K. A., & Jupiter, D. C. (2024). Charcot neuroarthropathy in diabetic patients in Texas. Primary Care Diabetes, 18(5), 533–538.
Schweitzer, M., & Rockhill, S. (2022). Conservative Management of Charcot Neuroarthropathy. Clinics in Podiatric Medicine and Surgery, 39(4), 585–594.
Pitocco, D., Scavone, G., Di Leo, M., et al. (2019). Charcot Neuroarthropathy: From the Laboratory to the Bedside. Current Diabetes Reviews, 16(1), 62–72.
Schmidt, B. M., & Holmes, C. M. (2018). Updates on Diabetic Foot and Charcot Osteopathic Arthropathy. Current Diabetes Reports, 18(10), 74.
Bansod, H., Wanjari, A., & Dumbhare, O. (2023). A Review on Relationship Between Charcot Neuroarthropathy and Diabetic Patients. Cureus, 15(12), e50988.
Comments
